PMID- 19474521
OWN - NLM
STAT- MEDLINE
DCOM- 20100217
LR  - 20211020
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
VI  - 32
IP  - 6
DP  - 2009 Jun
TI  - Effects of moderate-severe exercise on blood glucose in Type 1 diabetic 
      adolescents treated with insulin pump or glargine insulin.
PG  - 519-24
AB  - BACKGROUND: Few papers focus on exercise-related blood glucose (BG) in patients 
      on continuous sc insulin infusion (CSII) or multiple daily injections (MDI) with 
      glargine. AIM: The main objective was to evaluate the degree of glycemic control 
      in Type 1 diabetes mellitus adolescents on CSII doing physical activity with pump 
      switched on or off. These findings were also compared with a small group of 
      patients on MDI with glargine. SUBJECTS AND METHODS: Eight patients on CSII 
      (basal rate continued or turned off in alternating sessions) and 5 on MDI joined 
      4 sessions of moderate-severe exercise. RESULTS: Post-exercise BG significantly 
      increased with the pump off and was unchanged/decreased with the pump on and MDI 
      groups vs baseline. The hypoglycemia rate was not different among the 3 groups at 
      any time. Pump on: hypoglycemias more frequent both at bedtime (p=0.031) and at 
      awakening (p<0.001) than before dinner and at awakening than at bed-time 
      (p=0.044). Pump off: hypoglycemias more frequent both at bed-time (p=0.010) and 
      at awakening (p=0.031) than before dinner. MDI: no differences. CONCLUSIONS: 
      Glargine is safe and reducing the pre-lunch insulin is unnecessary. Subjects on 
      insulin pump should not stop the basal rate. If they stop the pump, some actions 
      are advisable: pre-exercise insulin bolus, pre-sleeping snack rich in 
      carbohydrates, slight reduction of the overnight basal rate. On the other hand, 
      if the basal rate is unmodified, the ingestion of sugary drinks during the 
      exercise, the reduction of the overnight basal rate, a reduction of the 
      pre-dinner insulin bolus and/or a pre-sleeping snack should be considered.
FAU - Delvecchio, M
AU  - Delvecchio M
AD  - Department of Biomedicine of Developmental Age, University of Bari, Bari, Italy.
FAU - Zecchino, C
AU  - Zecchino C
FAU - Salzano, G
AU  - Salzano G
FAU - Faienza, M F
AU  - Faienza MF
FAU - Cavallo, L
AU  - Cavallo L
FAU - De Luca, F
AU  - De Luca F
FAU - Lombardo, F
AU  - Lombardo F
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - 0 (Insulin Lispro)
RN  - 0 (Insulin, Long-Acting)
RN  - 2ZM8CX04RZ (Insulin Glargine)
SB  - IM
MH  - Adolescent
MH  - Blood Glucose/*metabolism
MH  - Child
MH  - Diabetes Mellitus, Type 1/*blood/*drug therapy
MH  - Female
MH  - Glycemic Index
MH  - Humans
MH  - Insulin/administration & dosage/*analogs & derivatives
MH  - Insulin Glargine
MH  - *Insulin Infusion Systems
MH  - Insulin Lispro
MH  - Insulin, Long-Acting
MH  - Male
MH  - Physical Fitness/*physiology
MH  - Statistics, Nonparametric
EDAT- 2009/05/29 09:00
MHDA- 2010/02/18 06:00
CRDT- 2009/05/29 09:00
PHST- 2009/05/29 09:00 [entrez]
PHST- 2009/05/29 09:00 [pubmed]
PHST- 2010/02/18 06:00 [medline]
AID - 10.1007/BF03346499 [doi]
PST - ppublish
SO  - J Endocrinol Invest. 2009 Jun;32(6):519-24. doi: 10.1007/BF03346499.